Results 171 to 180 of about 12,272 (217)

Utility of Iron Staining in Bone Marrow Aspirates in the Era of Next-Generation Sequencing: A Retrospective Single-Centre Study. [PDF]

Int J Lab Hematol
Ganeshalingam V, Kamel K.
europepmc   +1 more source

Essential HDRescue: A Co-Targeting Strategy to Enhance Precision Genome Editing by Co-Editing Essential Genes. [PDF]

Cells
Siwak JF, Connelly JP, Pruett-Miller SM.
europepmc   +1 more source

Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia. [PDF]

Oncologist
Zhao L, Cheng F, Wei J, Liu R, Zhao Q, Zhang Y, Li Y.   +6 more
europepmc   +1 more source

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? [PDF]

Blood Neoplasia
Komrokji RS, Komrokji Z, Al Ali NH, Xie Z, Chan O, Kuykendall AT, Walker AR, Yun S, Reynolds SB, Shallis R, Lancet JE, Sallman DA, Padron E.   +12 more
europepmc   +1 more source

Clinical Characteristics and Molecular Profiling of <i>SF3B1</i>-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice. [PDF]

Int J Mol Sci
Wang RR, Than H, Tham C, How GF, Khoo SJ, Tuy TT.   +5 more
europepmc   +1 more source

Splicing factor mutations clearance and outcomes in clonal myeloid neoplasms: a referral center experience. [PDF]

Ann Hematol
Tanariyakul M, Mott S, Daniels B, Yaganti A, Wannaphut C, Hornberg S, Dhakal P, Sutamtewagul G, Poonsombudlert K.   +8 more
europepmc   +1 more source

SF3B1 mutation as a predictive biomarker for luspatercept efficacy in myeloproliferative neoplasms and MDS/MPN: a clinical study. [PDF]

Ann Hematol
Cui T, Gong J, Zhang X, Zhang J, Wei N, Zheng W, Duan M.   +6 more
europepmc   +1 more source

Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification. [PDF]

Curr Hematol Malig Rep
Loghavi S, Hasserjian RP.
europepmc   +1 more source

SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer [PDF]

Cell Reports, 2022
Mutations in the splicing factor SF3B1 are frequently occurring in various cancers and drive tumor progression through the activation of cryptic splice sites in multiple genes. Recent studies also demonstrate a positive correlation between the expression
Gerald Schwank
exaly   +2 more sources

m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis [PDF]

Molecular Cell, 2023
SF3B1 is the most mutated splicing factor (SF) in myelodysplastic syndromes (MDSs), which are clonal hematopoietic disorders with variable risk of leukemic transformation. Although tumorigenic SF3B1 mutations have been extensively characterized, the role
Gabriele Todisco, Cristian Bellodi, Marios Dimitriou   +2 more
exaly   +3 more sources